Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 183

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 183
---
,000 shares authorized as of December 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023— — Common stock, $0.01 par value; 400,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 144,220,986 and 138,385,498 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively1,768 1,711 Additional paid-in capital2,764,880 2,144,811 Accumulated other comprehensive income2,020 643 Accumulated deficit(1,538,984)(1,116,211)Total stockholders’ equity 1,229,684 1,030,954 Total liabilities and stockholders’ equity$1,374,180 $1,153,917 

See accompanying notes to consolidated financial statements.

137

Table of Contents

Denali Therapeutics Inc.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

Year Ended December 31,202420232022Collaboration revenue:Collaboration revenue from customers(1)$— $330,531 $105,065 Other collaboration revenue— — 3,398 Total collaboration revenue— 330,531 108,463 Operating expenses:Research and development(2)396,440 423,876 358,732 General and administrative105,438 103,354 90,475 Total operating expenses501,878 527,230 449,207 Gain from divestiture of small molecule programs14,537 — — Loss from operations(487,341)(196,699)(340,744)Interest and other income, net64,636 51,505 14,774 Loss before income taxes(422,705)(145,194)(325,970)Income tax expense(68)(30)(21)Net loss(422,773)(145,224)(325,991)Other comprehensive income (loss):Net unrealized gain (loss) on marketable securities, net of tax1,377 7,529 (4,387)Comprehensive loss$(421,396)$(137,695)$(330,378)Net loss